Jordan Gauthier, MD, MSc, discusses the rationale for combining ibrutinib with CD19-targeting chimeric antigen receptor T cells for the treatment of patients with chronic lymphocytic leukemia.
Jordan Gauthier, MD, a senior clinical research fellow at Fred Hutchinson Cancer Research Center, discusses the rationale for combining ibrutinib (Imbruvica) with CD19-targeting chimeric antigen receptor (CAR) T cells for the treatment of patients with chronic lymphocytic leukemia (CLL).
While CAR T cells have been successful in aggressive lymphomas, acute lymphocytic leukemia, and non-Hodgkin lymphoma, the results have not been as good in CLL, Gauthier says. However, ibrutinib can be beneficial by helping CLL cells migrate from the lymph nodes to the peripheral blood and can help improve the functionality of the CAR T cells.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More